Despite rigid protocols, investigators must use their clinical judgment, informed by prior data, to enroll patients they believe will genuinely benefit. This patient-centric approach is viewed as not only ethical but also crucial for achieving a positive trial outcome, blending the art of medicine with the science of research.

Airway Therapeutics' clinical trial operates under extreme time pressure, as treatment must begin within four days of birth. This logistical constraint forces parents—already in shock and crisis—to make a rapid, complex decision about enrolling their infant, creating an immense emotional and ethical challenge for families and medical teams.

The FDA's conflict with Unicure over its Huntington's gene therapy highlights a significant philosophical shift. New leadership is demanding rigorous sham-controlled trials, involving drilling into patients' skulls for a placebo, a stark contrast to the previous, more flexible regime. This signals a much higher, potentially prohibitive, evidence bar for future gene therapies.

The FDA initially agreed uniQure could use the robust Enroll HD database for its control group, a standard practice for rare diseases. Their later reversal, demanding a new placebo trial, creates significant regulatory uncertainty, making it harder for companies to develop therapies for rare conditions.

For uniQure's Huntington's therapy, the FDA demands a placebo-controlled trial requiring patients to undergo a 14-18 hour sham brain surgery—a procedure European regulators deemed unethical. This creates a major barrier to proving the drug's efficacy for a fatal disease.

The lack of new drugs for pre-term babies is a market failure. For three decades, progress has been crippled by a dual challenge: venture capital funds avoiding pediatric studies and regulatory agencies lacking recent experience in evaluating neonatal treatments, creating a vicious cycle of stagnation.

The fastest, cheapest path to drug approval involves showing a small survival benefit in terminally ill patients. This economic reality disincentivizes the longer, more complex trials required for early-stage treatments that could offer a cure.

The approval of effective therapies like nirogacestat creates an ethical dilemma. For patients with progressing tumors, continuing to use a placebo arm in clinical trials may no longer be appropriate, challenging future research design for this rare disease.

The Unicure case exposes a critical hurdle for gene therapies requiring brain surgery. Patient advocates argue a "sham" placebo surgery is unethical due to risks like neurodegeneration. Yet, the FDA's potential rejection of an external control arm creates a development paradox, catching companies between patient safety ethics and regulatory demands for placebo data.